Kornimate/medical-research-clean huggingface dataset:
the study on the effectiveness and safety of electroacupuncture at st36 in treating primary premature ejaculation

Conditions: Premature Ejaculation

Summary: a pilot prospective single-arm cohort study on the effectiveness and safety of electroacupuncture at st36(zusanli) in treating primary premature ejaculation

this is a pilot prospective single-arm cohort study to verify the effectiveness and safety of electroacupuncture at st36(zusanli) in treating primary premature ejaculation, based on the result on animal study that daily electroacupuncture at st36(zusanli) for 30 days could delay the ejaculation of male sd rats.

Eligibility criteria:
inclusion criteria: 1. age 18 to 60 2. heterosexual, with a single, stable partner for more than 6 months 3. symptoms of primary premature ejaculation: complaints of ielt ≤ 1 min since the first sexual intercourse, and poor ability to control ejaculation leading to anxiety, annoyance, depression or/and avoidance of sexual life and other negative effects. exclusion criteria: 1. urinary system infection: urinary tract infection symptoms (such as urinary tract irritation symptoms, prostatitis symptoms, blood semen, etc.) or urine routine shows abnormal white blood cells and red blood cells 2. abnormal androgen: sex hormone examination shows abnormal androgen (testosterone) 3. systemic diseases: ask about medical history of hypertension, diabetes, alcohol dependence, coronary heart disease and mental disorders 4. organic abnormalities: abnormal development of external genitalia, bilateral testes, epididymis and spermatic cords with obvious abnormalities on palpation 5. history of surgery and trauma: dorsal nerve block of the penis, erectile function-related surgery, prostate surgery, pelvic surgery, etc. 6. influence of drugs: within one month before enrollment, have taken ssri, tramadol and other drugs to treat diseases 7. allergy to dapoxetine and lidocaine 8. history of drug, alcohol or substance abuse in the past 6 months 9. accompanied by erectile dysfunction: international index of erectile function-5 (international index of erectile function, iief-5) score ≤ 21 points

Keywords: premature ejaculation electroacupuncture st36
dbs recordings to characterize movement facilitation in parkinson's disease

Conditions: Parkinson Disease

Summary: several strategies or contexts help patients with parkinson's disease to move more quickly or normally, however the brain mechanisms underlying these phenomena are poorly understood. the proposed studies use intraoperative recordings during dbs surgery for parkinson's disease to understand the brain mechanisms supporting improved movements elicited by external cues. the central hypothesis is that distinct networks are involved in movement improvement depending on characteristics of the facilitating stimulus. participants will perform movement tasks during awake surgery performed exclusively for clinical indications. the identified biomarkers may provide targets for future neuromodulation therapies to improve symptoms that are refractory to current treatments, such as freezing of gait.

patients with parkinson's disease (pd) will perform computer tasks involving reaching and tapping movements during video recording of movements and electrophysiological recording of brain signals during deep brain stimulation surgery. experimental manipulations involve different computer stimuli that manipulate the presence or absence of sensory and motivational movement cues. the same experimental manipulations are delivered to all individual subjects. 40 pd patients who are undergoing deep brain stimulation (dbs) surgery for treatment of parkinson's disease, will perform the tasks during awake surgery and recordings will be obtained from 2 implanted dbs electrodes as well as 2 temporary electrode strips placed on the surface of the brain for research purposes. study procedures are limited to the intraoperative environment with no additional study visits. all patients will also be asked to perform clinical rating scales and questionnaires and undergo a movement disorders neurological exam.

Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic parkinson's disease based on presence of at least 2 cardinal pd features (tremor, rigidity, or bradykinesia) * undergoing deep brain stimulation surgery for treatment of advanced parkinson's disease, according to clinical evaluation, including the following criteria: * advanced idiopathic pd as determined by off unified parkinson's disease rating scale (updrs) part iii motor subscale \> 25 * l-dopa responsive symptoms with at least 30% improvement in updrs iii scores on vs. off medication or medication refractory disabling tremor * persistent disabling motor symptoms or drug side effects (dyskinesias, motor fluctuations, disabling "off" periods) despite optimal medical therapy * preoperative mri without evidence of cortical or subdural adhesions or vascular abnormalities * willingness and ability to cooperate during conscious operative procedure for up to 40 minutes exclusion criteria: * medical contraindication to surgery, including use of anticoagulant or antiplatelet therapy within 1 week * significant cognitive or psychiatric disease based on clinical neuropsychological testing

Keywords: deep brain stimulation neuromodulation external cueing movement
a study of intracellular signaling in muscle and fat cells during ketosis

Conditions: Ketoacidosis; Diabetes Mellitus Type 1

Summary: hypothesis 1. to define whether stimulation of atgl and suppression of g0/g1 switch gene occur in the initial phases of diabetic ketoacidosis and thus can be identified as the primary mechanisms behind this life threatening condition. 2. make a human model for studying ketoacidosis. the investigators plan to reduce in their regular insulin over night. in the morning we administer endotoxin, which together with a relative lack of insulin will initiate ketogenesis - a state of ketoacidosis. on another occasion strict glycemic control is imposed by means of intravenous insulin. the testing is done two separate days with at least 3 weeks in between and patients are admitted to hospital the evening before the day of testing. the investigators use isotopic tracers to determine metabolic fluxes and analyse fat (atgl, g0/g1 switch gene) and muscle biopsies.


Eligibility criteria:
inclusion criteria: * diabetes type 1 * 19 \< bmi \< 26 * minimal or negative c-peptide * written consent exclusion criteria: * severe comorbidity * regular medication apart from insulin
clinical treatment of refractory breast cancer based on organoid drug sensitivity results

Conditions: Refractory Breast Cancer

Summary: this study aims to enroll refractory breast cancer patients. patient-derived organoid will be established, and drug sensitivity test will be conducted to intervene in the selection of clinical treatment plans. efficacy evaluation and prognosis analysis will also be conducted. it is hoped that this study will provide a basis for the development of personalized treatment plans.

forty patients with refractory breast cancer who met the inclusion criteria were enrolled in the study after signing an informed consent form. tumor samples were obtained through clinical puncture, and qualified samples were subjected to organoid modeling. perform drug sensitivity test on the established breast cancer organoids. the drugs used are all that have been marketed and applied in clinical practice. according to the results of organoid drug sensitivity analysis, the patient received a treatment plan with relatively sensitive drugs. follow up prognostic data and relevant clinical information of enrolled patients, conduct statistical analysis on the consistency between drug sensitivity test results and patient treatment response, and evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity results.

Eligibility criteria:
inclusion criteria: 1. female, aged ≥ 18 years and ≤ 75 years old; 2. breast cancer confirmed by histology or cytology; 3. one of the following two conditions shall be met: a) operable breast cancer: recurrent progression during adjuvant therapy; or the time from initial treatment to the onset of disease progression is less than or equal to 2 years; b) non-operable breast cancer: patients who have changed two line treatment plans within 6 months; 4. being able to obtain sufficient fresh tissue specimens for organoid establishment through puncture; 5. expected survival time ≥ 3 months; 6. the patient voluntarily joined this study and signed an informed consent form (icf), with good compliance and cooperation in follow-up. exclusion criteria: 1. pregnant and lactating women; 2. patients who have clinically significant (i.e. active) heart disease (such as congestive heart failure, symptomatic coronary artery disease, arrhythmia, etc.) or myocardial infarction within the past 12 months; 3. individuals with a history of abuse of psychotropic drugs who are unable to quit or have mental disorders; 4. the researchers believe that patients are not suitable for inclusion.
comparison of laryngeal masks in urethral cystoscopic surgery operations: a prospective randomized clinical study

Conditions: Ureteral Calculi

Summary: the use of laryngeal masks are increased.this study aimed to compare lma pro seal and baska -mask in urethral retrograde sistoscopy operations.

the use of laryngeal masks are increased. aimed to compare lma pro seal and baska -mask in urologic retrograde sistoscopy operations. asa 1-2 80 subjects who is undergoing elective urs operations were enrolled in this prospective randomized clinical study. the demographic and airway characteristics of patients preoperatively and lam insertion times, nasogastric insertion times number of intubation attempts, fiberoptic grades from the lam, expired tidal volume, oropharyngeal leak pressures, peak and mean airway pressures preoperatively, minor complications like sore throat, hoarseness, dysphagia were recorded at the postoperative care unit.

Eligibility criteria:
inclusion criteria:18-65 years of age * undergoing elective urs operations * bmı\<35 * asa i-ii exclusion criteria:\<18 years of age * bmı\>35 * asa iii-iv

Keywords: baska-mask proseal urs
effect of aerobic exercises on trace elements in post-menopausal women after radiotherapy

Conditions: Trace Elements Levels After Breast Cancer Radiotherapy

Summary: this study will be conducted on 28 participants who are survivors of breast cancer and underwent radiotherapy. the purpose of the current study is to investigate the effect of aerobic exercises on quality of life and serum levels of zinc, copper and iron in post-menopausal women who received radiotherapy after surviving breast cancer.

breast cancer (bc) is the most common type of cancer in women globally. several studies observed changes in the serum blood levels of trace elements in bc. essential trace elements have relevant functions in a large number of cellular processes, with multiple roles in the correct functioning of metabolic enzymes. there were previous trials to investigate the effect of exercise on trace elements in different populations as in the elite sportsmen. some other studies to investigate the effect of exercise on breast cancer survivors for instance (duijts et al., 2011) stated that physical exercise has effects on psychosocial functioning and health-related quality of life in breast cancer patients and survivors. also, (lambrigts et al., 2022) stated that aerobic exercise is the possible easiest solution to improve quality of life. lastly, (lipsett et al., 2017) proved that exercise during adjuvant radiotherapy for breast cancer has positive impact on reducing fatigue and improve quality of life . however, there are no previous studies to investigate the effect of exercise on trace elements in bc patients nor identifying the optimal dose or parameters of the exercise. so, this study is an attempt to add to the clinical knowledge in this field as it will be the first one that investigates the effect of aerobic exercise on trace elements in women survived bc.

Eligibility criteria:
inclusion criteria: * all postmenopausal women with breast cancer and received radiotherapy immediately at the end of radiotherapy or max six months to one year in each group. after clinically diagnosed by oncologist with breast cancer stage i and ii . * their ages will range from 50-60 years old. * good general health (ecog performance status 0-1). * voluntary acceptance of participation in the study. exclusion criteria: * systematic chronic diseases (respiratory diseases, cardiovascular diseases...etc) * cognitive dysfunction as well as neuromuscular or musculoskeletal impairment or disease affecting postural control or motion pattern. * professional athletes.

Keywords: trace elements breast cancer aerobic exercise
prophylactic hqp1351 therapy post-transplants on leukemia after allo-hsct

Conditions: Prophylactic HQP1351 Therapy; Third Generation TKI

Summary: allogeneic hematopoietic stem cell transplantation (allo-hsct) improves the long-term outcomes for philadelphia chromosome-positive acute lymphoblastic leukemia (ph+ all) and bc-cml. relapse remains a major cause of treatment failure even after allo-hsct. the prevention of relapse is essential for improving the outcome of ph+ all. pre-emptive tyrosine kinase inhibitor (tkis) administration based on minimal residual disease (mrd) and bcr-abl mutation after allo-hsct might reduce the incidence of relapses and improve survival for patients with ph+ luekemia. in this study, we will evaluate the safety and efficacy of newly third tki-hqp1351 therapy post-transplants on ph+ leukemia after allo-hsct with mrd positive pre-transplants.


Eligibility criteria:
inclusion criteria: 1. patient age of 18-65 years 2. ph+ luekemia(includ ph+all and cml) undergoing allo-hsct with mrd positive pre-transplants 3. survival \> 30 days post-transplants 4. laboratory parameters as defined below: serum creatinine less than or equal to 2.0 x uln ast and alt less than or equal to 3 x uln (less than or equal to 5 x uln if unequivocal liver gvhd),total bilirubin less than or equal to 3 x uln 5. ability to understand and willingness to sign a written informed consent form exclusion criteria: 1. ph+ all undergoing allo-hsct with mrd negative pre-transplants 2. survival \<30 days post-transplants 3. mrd positive on day +30 post-transplants 4. any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) 5. patients with any conditions not suitable for the trial (investigators' decision)

Keywords: cml ph+ all hqp1351 prophylactic therapy
treatment of adult-onset immunodeficiency with bortezomib

Conditions: Adult-onset Immunodeficiency

Summary: this is pilot study aimed to investigate the application of proteosome inhibitor, bortezomib in treatment of patients with neutralizing autoantibody to ifn-γ. the investigators hypothesis is that bortezomib will reduce the antibody level and restore interferon-gamma function, resulting in clinical improvement and should be well-tolerated and safe for use in patients with autoantibody to ifn-γ.

the patients with autoantibody to ifn-γ and past or current history of proven opportunistic infection will receive 2 treatment cycles of bortezomib subcutaneously (4 injections of 1.3 mg bortezomib /m2 body surface per cycle), followed by low dose oral cyclophosphamide for 4 month after completion treatment with bortezomib.

Eligibility criteria:
inclusion criteria: * age 21 - 60 years * positive anti-interferon-gamma autoantibody * anti-hiv negative * past or current infection with opportunistic infection (oi) such as nontuberculous mycobacteria, proven by culture * ability to give written consent, informed written consent * negative pregnancy test in premenopausal woman * receving antimicrobial for treatment of oi for at least one month. exclusion criteria: * pregnancy or lactation * absolute neutrophil count \<1.5 × 109/ l or platelet count \<100× 109/ l or hemoglobin level \< 8 g/dl * past history of myocardial infarction or heart failure within 6 months before enrollment or prolonged qt interval \> 450 msec at screening * renal insufficiency (gfr \< 30 ml/min) * abnormal liver function test (ast\> 3 times of unl) * known cancer or receiving other immunosuppressive agent * known intolerability to bortezomib

Keywords: anti-interferon gamma autoantibody
sabr including regional lymph node irradiation for patients with high risk prostate cancer (saturn)

Conditions: Prostate Cancer

Summary: current treatment options for high risk localized prostate cancer include radical prostatectomy +/- postoperative radiotherapy, radical radiotherapy with androgen deprivation therapy. evidence has emerged that prostate cancer has a low α/β ratio in the range of 1-3 gy. even with high risk tumors, prostate cancer is hypothesized to have a greater sensitivity to large fraction sizes and high dose per fraction radiotherapy theoretically allows for biological dose escalation with fewer visits and no additional toxicity. therefore, we hope to determine the toxicity, quality of life, biochemical and pathological control of sbrt for high risk prostate cancer incorporating eni.


Eligibility criteria:
inclusion criteria: * informed consent obtained * men \> 18 years of age * histologically confirmed prostate adenocarcinoma (centrally reviewed) * high risk prostate cancer, defined as at least one of clinical stage t3 or gleason 8-10, or psa \> 20ng/ml exclusion criteria: * prior pelvic radiotherapy * anticoagulation medication (if unsafe to discontinue for gold seed insertion) * diagnosis of bleeding diathesis * large prostate (\>90cm3) on imaging at time of gold seed insertion * no evidence of castrate resistance (defined as psa \< 3ng/ml while testosterone is \< 0.7nmol/l * definitive regional or distant metastatic disease on staging investigations

Keywords: stereotactic ablative radiotherapy androgen deprivation therapy
comparison of lornoxicam and paracetamol for pre-emptive intravenous analgesia for elective inguinal hernia repair

Conditions: Inguinal Hernia; Postoperative Pain

Summary: the purpose of this study is to determine whether lornoxicam or paracetamol is more effective in providing pre-emptive analgesia for adult patients undergoing elective unilateral inguinal hernia repair under general anesthesia.

early postoperative pain is the major cause that may restric physical activity of the patients and delay in returning work. newer non-steroid analgesic drugs (nsad) can be helpful in overcoming this problem, especially in pre-emptive use. in this prospective randomized placebo controlled double blinded study we aimed to determine whether lornoxicam, as a nsad, or paracetamol is more effective in providing pre-emptive analgesia for patients undergo elective unilateral inguinal hernai repair under general anesthesia. 60 patients above the age of 18, asa score of i to iii will be assigned into 3 groups. all the patients will be operated under general anesthesia. recurrent hernia cases, pregnant or lactated women, patients allergic to the two drugs, patients with documented gastric disorders or bleeding disorder or under anticoagulent therapy will be excluded. group designs: group i: 100 ml intravenous saline infusion as placebo 30 minitues before the surgery. group ii: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery. group iii: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery. all patients will receive patient controlled intravenous analgesia with morphine for 24 hours postoperatively. postoperative pain levels will be determined by vas (visual analog scale) and morphine consumption will be recorded. patients will be prescribed with oral paracetamol (300 mg) plus codein (15 mg)at discharge at the end first 24 hours. patients will be asked to record daily consumption of given analgesic, pain response to physical activity by using likert scale, and vas scores daily. the first follow-up examination will take place on day-7. the patients will be asked to keep recording the same parameters until the second hospital visit at 4th week. on the follow-up examination at 4th week quality of life will be determined by sf-36 form. the results will be analyzed using spss for windows software.

Eligibility criteria:
inclusion criteria: * inguinal hernia * unilateral hernia * general anesthesia * elective repair exclusion criteria: * drug allergy * bilateral hernia * local anesthesia * local blockade * regional anesthesia * emergency surgery * complicated hernia * recurrent hernia

Keywords: inguinal hernia surgery general anesthesia analgesia pre-emptive sf36
the effect of probiotics on gut microbiotain after helicobacter pylori eradication

Conditions: Helicobacter Pylori Infection; Infections; Intestinal Bacteria Flora Disturbance

Summary: the purpose of this study is to evaluate the effect of probiotics during vonoprazan-amoxicillin dual therapy on the gut microbiota in helicobacter pylori eradication and to investigate whether the eradication rate of h.pylori will be improved when adding probiotics

after being informed about the study and potential risks, all patients giving written informed consent will undergo a 1-week screening period to determine eligibility for study entry. at week 0, patients who meet the eligibility requirement will be included in this simultaneous blind test. a total of 100 patients with hp infection were enrolled in this study. all patients were randomly divided into two groups according to the ratio of 1:1. group a was given vonoprazan 20mg bid, amoxicillin 1000mg tid, probiotics 3tabltes tid for 14 consecutive days; group b was given vonoprazan 20mg bid and amoxicillin 1000mg tid for 14 days. on the 14th days of treatment, the researchers will follow up the patients' adverse reactions and medication compliance. the feces of the subjects were collected one day before the treatment, and on the 14th and 42th days after the treatment; after 4 weeks of drug withdrawal, all subjects will be reexamined with 13c-ubt.

Eligibility criteria:
inclusion criteria: 1. ages between 18 and 65 years; sexes eligible for study: both; 2. patients who are diagnosed with helicobacter pylori; 3. treatment-naive patients or patients who failed to eradicate helicobacter pylori in the past but haven't undergone eradication therapy in the past six months; 4. voluntary to be involved in the study and written informed consent was obtained from all patients exclusion criteria: 1. allergic reactions to the study drugs; 2. patients with peptic ulcer; 3. patients who underwent eradication therapy for helicobacter pylori during the last six months; 4. patients who took antibiotics,bismuth agents,probiotics within four weeks prior to treatment and those who took h2 receptor antagonists,proton pump inhibitors(ppis) or potassium competitive acid blockers within two weeks prior to treatment; 5. patients who are taking glucocorticoids, non-steroidal anti-inflammatory drugs or anticoagulants; 6. patients who have history of esophageal or gastric surgery; 7. pregnant or lactating women; 8. patients who have severe concurrent diseases such as hepatic,cardiovascular,respiratory,renal disorders or malignancies; 9. alcohol abusers